U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07332455) titled 'First-Time-in-Human Study of GSK5471713 in Adults With mCRPC' on Jan. 09.
Brief Summary: This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
Study Start Date: Feb. 27
Study Type: INTERVENTIONAL
Condition:
Neoplasms, Prostate
Intervention:
DRUG: GSK5471713
GSK5471713 will be administered at different dose levels based on the dose escalation study design
Recruitment Status: NOT_YET_RECRUITING
Sponsor: GlaxoSmithKline
Disclaimer: Curated by HT Syndication....